tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders StocksMarket MoversTipRanks 50 IndexDividend StocksAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA

NAMS Stock Latest News

NewAmsterdam Pharma participates in a conference call with Cantor Fitzgerald
The FlyNewAmsterdam Pharma participates in a conference call with Cantor Fitzgerald
8h ago
NAMS
NewAmsterdam Pharma initiated with a Buy at Citi
PremiumThe Fly
NewAmsterdam Pharma initiated with a Buy at Citi
11d ago
NAMS
Strong Buy Recommendation for NewAmsterdam Pharma Driven by Promising Cardiovascular and Alzheimer’s Opportunities
PremiumRatings
Strong Buy Recommendation for NewAmsterdam Pharma Driven by Promising Cardiovascular and Alzheimer’s Opportunities
16d ago
NAMS
NewAmsterdam Pharma Schedules R&D Day for June 2025
PremiumCompany Announcements
NewAmsterdam Pharma Schedules R&D Day for June 2025
17d ago
8K
NAMS
NewAmsterdam Pharma initiated with a Buy at Stifel
PremiumThe Fly
NewAmsterdam Pharma initiated with a Buy at Stifel
18d ago
NAMS
Promising Alzheimer’s Drug Development Fuels Buy Rating for NewAmsterdam Pharma
PremiumRatingsPromising Alzheimer’s Drug Development Fuels Buy Rating for NewAmsterdam Pharma
19d ago
NAMS
NewAmsterdam Pharma: Promising Growth Potential with Innovative Alzheimer’s Biomarker and LDL Reduction Strategies
Premium
Ratings
NewAmsterdam Pharma: Promising Growth Potential with Innovative Alzheimer’s Biomarker and LDL Reduction Strategies
19d ago
NAMS
NewAmsterdam Pharma Announces Positive Phase 3 Trial Results
Premium
Company Announcements
NewAmsterdam Pharma Announces Positive Phase 3 Trial Results
19d ago
8K
NAMS
NewAmsterdam Pharma announces topline data from BROADWAY clinical trial
PremiumThe Fly
NewAmsterdam Pharma announces topline data from BROADWAY clinical trial
19d ago
NAMS
NewAmsterdam Pharma Approves Key Proposals at AGM
PremiumCompany Announcements
NewAmsterdam Pharma Approves Key Proposals at AGM
21d ago
8K
NAMS
NewAmsterdam Pharma initiated with an Overweight at Cantor Fitzgerald
PremiumThe Fly
NewAmsterdam Pharma initiated with an Overweight at Cantor Fitzgerald
24d ago
NAMS
Buy Rating Affirmed for NewAmsterdam Pharma: Obicetrapib’s Promising Clinical Profile and Market Potential Highlighted
PremiumRatings
Buy Rating Affirmed for NewAmsterdam Pharma: Obicetrapib’s Promising Clinical Profile and Market Potential Highlighted
24d ago
NAMS
Strong Investment Potential for NewAmsterdam Pharma’s Obicetrapib Due to Cardiovascular and Metabolic Benefits
PremiumRatingsStrong Investment Potential for NewAmsterdam Pharma’s Obicetrapib Due to Cardiovascular and Metabolic Benefits
25d ago
NAMS
Buy Rating for NewAmsterdam Pharma: Obicetrapib’s Potential in Cardiovascular Risk Reduction and Revenue Growth
Premium
Ratings
Buy Rating for NewAmsterdam Pharma: Obicetrapib’s Potential in Cardiovascular Risk Reduction and Revenue Growth
1M ago
NAMS
Strong Financial Position and Promising Cardiovascular Developments Propel NewAmsterdam Pharma’s Growth Potential
Premium
Ratings
Strong Financial Position and Promising Cardiovascular Developments Propel NewAmsterdam Pharma’s Growth Potential
2M ago
NAMS
NewAmsterdam Pharma Reports Q1 2025 Financial Results
PremiumCompany Announcements
NewAmsterdam Pharma Reports Q1 2025 Financial Results
2M ago
NAMS
Buy Rating Affirmed for NewAmsterdam Pharma: Strategic Progress and Financial Stability Drive Confidence
PremiumRatings
Buy Rating Affirmed for NewAmsterdam Pharma: Strategic Progress and Financial Stability Drive Confidence
2M ago
NAMS
NewAmsterdam Pharma’s Promising Phase III Results and Strategic Plans Garner Buy Rating
PremiumRatings
NewAmsterdam Pharma’s Promising Phase III Results and Strategic Plans Garner Buy Rating
2M ago
NAMS
NewAmsterdam Pharma reports Q1 revenue $2.978M, consensus $1.46M
PremiumThe Fly
NewAmsterdam Pharma reports Q1 revenue $2.978M, consensus $1.46M
2M ago
NAMS
NewAmsterdam Pharma Presents Promising Phase 3 Trial Data
PremiumCompany AnnouncementsNewAmsterdam Pharma Presents Promising Phase 3 Trial Data
2M ago
8K
NAMS
NewAmsterdam Pharma announces additional data from BROADWAY, TANDEM studies
Premium
The Fly
NewAmsterdam Pharma announces additional data from BROADWAY, TANDEM studies
2M ago
NAMS
NewAmsterdam Pharma Appoints Adele Gulfo to Board
Premium
Company Announcements
NewAmsterdam Pharma Appoints Adele Gulfo to Board
2M ago
8K
NAMS

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >